All reports

All KCE reports are available in Dutch, French and English under several formats. Form and language of the reports

Publication year:
General domain:
Specific domain:

  1. A quadrivalent vaccine against serogroup B meningococcal disease: a cost-effectiveness study

    KCE Reports 231 (2014)

    https://kce.fgov.be/en/a-quadrivalent-vaccine-against-serogroup-b-meningococcal-disease-a-cost-effectiveness-study

  2. [Economic evaluation of antiviral treatment of chronic hepatitis B in Belgium]

    KCE Reports 157 (2011)

    https://kce.fgov.be/en/economic-evaluation-of-antiviral-treatment-of-chronic-hepatitis-b-in-belgium

  3. Cost-effectiveness of antiviral treatment of chronic hepatitis B in Belgium. Part 1: Literature review and results of a national study

    KCE Reports 127 (2010)

    https://kce.fgov.be/en/cost-effectiveness-of-antiviral-treatment-of-chronic-hepatitis-b-in-belgium-part-1-literature-review

  4. Pharmaceutical and non-pharmaceutical interventions for Alzheimer’s Disease, a rapid assessment

    KCE Reports 111 (2009)

    https://kce.fgov.be/en/pharmaceutical-and-non-pharmaceutical-interventions-for-alzheimer%E2%80%99s-disease-a-rapid-assessment

  5. Tiotropium in the Treatment of Chronic Obstructive Pulmonary Disease: Health Technology Assessment

    KCE Reports 108 (2009)

    https://kce.fgov.be/en/tiotropium-in-the-treatment-of-chronic-obstructive-pulmonary-disease-health-technology-assessment

  6. Pharmacological and surgical treatment of obesity. Residential care for severely obese children in Belgium.

    KCE Reports 36 (2006) August 2006 (3rd edition ; 2nd edition : July 2006 ; 1st edition : June 2006)

    https://kce.fgov.be/en/pharmacological-and-surgical-treatment-of-obesity-residential-care-for-severely-obese-children-in

  7. Trastuzumab in Early Stage Breast Cancer

    KCE Reports 34 (2006) 30 June (2nd edition; 22 June 2006, 1st edition)

    https://kce.fgov.be/en/trastuzumab-in-early-stage-breast-cancer

  8. [Effectiveness and cost-effectiveness of treatments for smoking cessation]

    KCE Reports 1 (2004) 22 juillet 2004 (1st print), août 2005 (2nd print)

    https://kce.fgov.be/en/effectiveness-and-cost-effectiveness-of-treatments-for-smoking-cessation

  9. Use of pneumococcal vaccines in the elderly: an economic evaluation

    KCE Reports 274 (2016) Supplementary material pdf fileR274_Supplementary-file_Univariate-sensitivity-analyses (13.95 MB) pdf fileR274_Supplementary-file_Sensitivity-analyses_PPV23-price (1.1 MB) pdf fileR274_Supplementary-file_Multivariate-sensitivity-analyses_Net-benefit-Box-plots (1.16 MB) pdf fileR274_Supplementary-file_Multivariate-sensitivity-analyses_CEAFs-and-CE-planes (58.74 MB) The results are also available in a searchable spreadsheet-database format for all scenario and sensitivity analyses.

    https://kce.fgov.be/en/use-of-pneumococcal-vaccines-in-the-elderly-an-economic-evaluation

  10. Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C

    KCE Reports 276 (2016)

    https://kce.fgov.be/en/economic-evaluation-of-novel-direct-acting-antiviral-daa-treatment-strategies-for-chronic-hepatitis

  11. Policies for Rare Diseases and Orphan Drugs

    KCE Reports 112 (2009)

    https://kce.fgov.be/en/policies-for-rare-diseases-and-orphan-drugs
  12. Senior couple on contry bike

    Statins for the primary prevention of cardiovascular events

    KCE Reports 306 (2019) A healthy lifestyle remains the most effective way of avoiding cardiovascular diseases and their consequences. Yet since 2002, the annual number of people who use cholesterol-lowering drugs from the statin family increased from 400,000 to 1,500,000. Currently, 25% of the population aged 40 and above take these drugs. Despite decreases in price due to the fact that all statins now exist in generic form, their total cost still stands at 160 million euros annually.

    https://kce.fgov.be/en/statins-for-the-primary-prevention-of-cardiovascular-events
  13. Children in a playground

    Cost-effectiveness analysis of HPV vaccination of boys in Belgium

    KCE Reports 308 (2019) The vaccine for the human papilloma virus (HPV) which causes cervical cancer was introduced about ten years ago in Belgium, but only girls benefit from it. However, it is now established that this same virus is also involved in other cancers, including throat cancer. The recommendations have thus been reviewed and here, as in most western countries, it is now recommended to vaccinate boys too.

    https://kce.fgov.be/en/cost-effectiveness-analysis-of-hpv-vaccination-of-boys-in-belgium